CCR4/CD194 recombinant proteins and antibodies

C-C Chemokine Receptor 4 (CCR4), also known as CD194 or CMKBR4, is an important chemokine receptor belonging to the C-C chemokine receptor family. It is primarily expressed on immune cells, including T cells, regulatory T cells (Tregs), and certain tumor cells. CCR4 plays a crucial role in immune regulation, particularly in immune tolerance, immune suppression, and tumor immune evasion. Research has shown that CCR4 expression is elevated in various tumor types, especially in certain T-cell lymphomas (such as peripheral T-cell lymphoma and cutaneous T-cell lymphoma) and some solid tumors, making it an ideal tumor-specific target for immune therapies.

CCR4 exerts its effects by binding to its ligands, such as CCL17 and CCL22, which promote T-cell migration and immune suppression. In the tumor microenvironment, CCR4 recruits regulatory T cells, allowing tumors to evade the immune system’s attacks. Thus, inhibition of CCR4 can enhance anti-tumor immune responses, making it a promising target in cancer immunotherapy.

Currently, ongoing drug development targeting CCR4 mainly focuses on monoclonal antibodies and immune checkpoint inhibitors. Some monoclonal antibodies, such as KHK2823, as well as other CCR4 inhibitors, are in preclinical and clinical trial stages, showing potential to inhibit T-cell migration and enhance anti-tumor immunity. Furthermore, research is underway to combine CCR4-targeted therapies with other immune checkpoint inhibitors (such as PD-1 or CTLA-4) in combination therapies to improve efficacy.

With the growing recognition of CCR4’s potential, several pharmaceutical companies have entered the field and are actively developing therapies targeting this receptor. Notable companies like Takeda, Amgen, and Gilead have invested significant resources into the development of CCR4-targeted treatments, particularly in the treatment of T-cell lymphomas and other hematologic malignancies, with early clinical successes. These companies aim to provide more precise and effective treatment options for cancer patients, especially for those with tumors that are resistant to traditional therapies.

To assist in the development of CCR4 targeted therapies, DIMA BIOTECH can now provide a full range of products and services for CCR4 targets. Products include active proteins, reference antibodies, and FC-verified monoclonal antibodies; services include customized services for antibodies against multiple genus proteins, antibody humanization, and affinity maturation services. In addition, to accelerate the development of CCR4 biotherapy, DIMA BIOTECH has also prepared a CCR4 target single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days; at the same time, we have currently screened out multiple CCR4 IgG sequence ready to out-liscensing, and customers can get the molecules for functional evaluation and verification the next day.